Biotech Breakthroughs and Bold Pivots: Inside Lepu's Profitability and the Robotics Rush

The narrative across Hong Kong’s diverse sectors this week is defined by structural shifts—some finally paying off, and others just beginning their costly journeys.

The standout is Lepu Biopharma (2157.HK). After years of heavy R&D burn, the company crossed a major threshold by turning its first profit in the first half of 2025. Fueled by surging sales of its PUYOUHENG injection and a strategic licensing deal, the biotech firm is gaining serious momentum, further validated by a breakthrough therapy designation from regulators in August 2025.

A stark contrast can be found in the restructuring of Hong Kong Robot Group (0370.HK). Formerly a textile player, the company officially rebranded in 2025 to chase the robotics financing boom. While the pivot drove a 60% revenue spike to HKD 186 million in FY2026, it came at a steep price: net losses widened to HKD 175.6 million. It’s a classic case of growing pains in a brand-new sector.

Meanwhile, legacy operators are playing to their strengths. Crystal International Group (2232.HK) reported a robust net profit of HKD 985.7 million for the first half of 2026, proving that apparel manufacturing still holds reliable margins. On the infrastructure side, China Merchants Port (0144.HK) continues to reward patient capital, lining up its next dividend payout for late 2026.

Also on the radar:

• Huicong Group (2495.HK) finalized its corporate name change in July 2026 as it doubles down on AI-driven audio-video solutions for enterprise clients.
• In the life sciences space, Peijia Medical (8367.HK) and The United Laboratories (3933.HK) remain focused on expanding their respective clinical and commercial footprints.
• Industrial and service staples—including IT leasing provider Edianyun (2279.HK), handbag maker Wah Sun Handbags International (1927.HK), and logistics container heavyweight CIMC (1282.HK)—continue to navigate the broader macro environment through operational optimization.